

INDEPENDENT AUDITORS' REPORT

To the Members of Biochem Pharmaceutical Private Limited

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of **Biochem Pharmaceutical Private Limited** ('the Company'), which comprise the Balance Sheet as at 31st March 2026, the Statement of Profit and Loss (including other comprehensive income), the Statement of changes in Equity and the Statement of cash flows for the year then ended, and notes to the financial statements, including a summary of material accounting policies and other explanatory information ("the Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ('the Act') in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ('Ind AS') and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2026, and its loss, total comprehensive income, the changes in equity and cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the financial statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the financial statements.

Information other than the Financial Statements and Auditor's Report thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Directors' Report, but does not include the financial statements and our audit reports thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the financial statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a) Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- d) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e) Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Financial Statements

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

As required by Section 143(3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept, so far as it appears from our examination of those books. The backup of the books of account and other books and papers maintained in electronic mode, has been maintained on daily basis on servers physically located in India during the year.
- c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, the Cash Flow Statement and Statement of Changes in Equity dealt with by this report are in agreement with the books of account.
- d) In our opinion, the aforesaid financial statements comply with the Ind AS specified under Section 133 of the Act.
- e) On the basis of the written representations received from the directors as on March 31, 2026 taken on record by the Board of Directors, none of the directors, is disqualified as on March 31, 2026 from being appointed as a director in terms of section 164(2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in “Annexure B” attached to this report. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company’s internal financial controls over financial reporting.
- g) With respect to the other matters to be included in the Auditor’s Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, no remuneration paid by the company to its directors during the year.
- h) With respect to the other matters to be included in the Auditor’s Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.
 - iv. (a) The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other persons or entities, including foreign entities (“Intermediaries”), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend to or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - (b) The management has represented that, to the best of its knowledge and belief, no funds have been received by the company from any persons or entities, including foreign entities (“Funding Parties”), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
 - (c) Based on such audit procedures that we have considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations given under (a) and (b) above, contain any material misstatement.
- v. During the year, the company has not declared any dividends. Hence, reporting of compliance under section 123 of the Companies Act, 2013 is not applicable.

- vi. Based on our examination, which included test checks, the Company has used accounting software for maintaining its books of account for the financial year ended 31st March 2026 which has a feature of recording audit trail (edit log) facility and the same has been operational throughout the year for all relevant transactions recorded in the accounting software. Further, during our audit, we did not come across any instance of audit trail feature being tampered with and the audit trail has been preserved by the company as per the statutory requirements for record retention.

For **MUKESH M. SHAH & CO.,**
Chartered Accountants
Firm Registration No.: 106625W

Place: Ahmedabad
Date: April 30, 2026
UDIN: 26129675BZFBWK2166

sd/-
Karnik K. Shah
Partner
Membership No.: 129675

“Annexure A” to the Independent Auditors’ Report

The Annexure referred to in Independent Auditors’ Report to the members of the Company on the financial statements for the year ended March 31, 2026.

Based on the audit procedures performed for the purpose of reporting a true and fair view on the financial statements of the Company and taking into consideration the information and explanations given to us and the books of account and other records examined by us in the normal course of audit, and to the best of our knowledge & belief, we state that:

- (i) The Company does not hold any Property, Plant and Equipment and intangible assets, hence, reporting under this clause of the order is not applicable to the company for the year.
- (ii)
 - (a) The company does not deal in any inventory; hence, reporting under this clause is not applicable to the company for the year.
 - (b) According to the information and explanations given to us and based on the records examined by us, at any point of time of the year, the Company has not been sanctioned any working capital facility from banks or financial institutions in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets. Accordingly, reporting under this clause of the Order is not applicable.
- (iii) According to the information and explanations given to us and on the basis of our examination of the records, the Company has not provided loans, advances in nature of loan, stood guarantee or provided security to a company, firms, limited liability partnerships or any other parties during the year. Accordingly, reporting under this clause of the order is not applicable.
- (iv) According to the information and explanations given to us and on the basis of our examination of the records, the Company has not given any loans, guarantees or security or made any investments to which provisions of section 185 and 186 of the Act is applicable, accordingly, reporting under this clause of the Order is not applicable to the Company.
- (v) According to the information and explanations given to us, the Company has not accepted any deposits within the meaning of the provisions of section 73 to 76 of the Act or any other relevant provisions of the Act and the rules framed thereunder. Further, according to the information and explanations given to us, no order has been passed by the Company Law Board or National Company Law Tribunal or Reserve Bank of India or any court or any other Tribunal, in this regard.
- (vi) As per the information and explanations provided to us, the company is not required to maintain the cost records pursuant to the Companies (Cost Records and Audit) Rules, 2014, as amended prescribed by the Central Government under sub-section (1) of section 148 of the Act, hence, reporting under this clause is not applicable to the company.
- (vii)
 - (a) The undisputed statutory dues in respect of Goods and Services tax, Provident Fund, Employees’ State Insurance, Income-tax, Sales-tax, Service tax, Duty of Custom, Duty of Excise, Value added Tax, Cess are not applicable to the company during the year. Moreover, as at 31st March, 2026. Further, there were no undisputed amounts payable in respect of Goods and Service tax, Provident Fund, Income-tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, cess and other material statutory dues in arrears as at March 31, 2026 for a period of more than six months from the date they became payable.
 - (b) There are no dues referred to in sub clause (a) above which have been under dispute as on 31st March, 2026.
- (viii) According to the information and explanations given to us, there were no transactions relating to previously unrecorded income that were surrendered or disclosed as income in the tax assessments under the Income Tax Act, 1961 (43 of 1961) during the year.

- (ix)
 - (a) The company has not taken any loans or other borrowings from any lender during the year; hence, reporting under this clause of the order is not applicable.
 - (b) The Company has not been declared willful defaulter by any bank or financial institution or other lender.
 - (c) The company has not taken any term loans during the year. Hence, reporting under this clause of the order is not applicable.
 - (d) The company has not raised any funds on short term basis during the year. Hence, reporting under this clause of the order is not applicable.
 - (e) The company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures.
 - (f) The Company has not raised any loans during the year on the pledge of securities held in its Subsidiaries, joint ventures or associate companies of the Company.
- (x)
 - (a) The Company did not raise any money by way of initial public offer or further public offer (including debt instruments) during the year and hence, reporting under this clause of the Order is not applicable to the Company.
 - (b) The Company has made preferential allotment of equity shares during the year and has complied with the requirements of applicable provisions of section 42 and section 62 of the Companies Act, 2013. Further, the funds raised by issuance of Equity shares have been used by the company for the purposes for which the funds were raised.
- (xi)
 - (a) To the best of our knowledge and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the year.
 - (b) According to the information and explanations given to us, no report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and up to the date of this report.
 - (c) As represented to us by the Management, there is no whistle blower complaints received by the Company during the year.
- (xii) The Company is not a Nidhi company. Accordingly, reporting under this clause of the Order is not applicable to the Company.
- (xiii) In our opinion and according to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with section 177 and 188 of the Act, where applicable, and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- (xiv) In our opinion and according to the information and explanations given to us, the requirements of having an internal audit system is not applicable to the company as the turnover, outstanding loans or borrowings from banks or financial institutions does not exceed the defined threshold as per the rules of the Act in the immediately preceding year. Accordingly, reporting under these clauses of the Order is not applicable to the Company.
- (xv) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into any non-cash transactions with any of their directors or persons connected with them and, hence, provisions of section 192 of the Act is not applicable to the company. Accordingly, reporting under this clause of the Order is not applicable to the Company.
- (xvi)
 - (a) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act 1934.

- (b) The Company has not conducted any non-banking or housing finance activities during the year.
- (c) The Company is not a Core Investment Company, as defined in the regulations made by the Reserve Bank of India.
- (d) The Group (as per the provisions of the Core Investment Companies (Reserve Bank) Directions, 2016) does not have more than one Core Investment Company.
- (xvii) The company has incurred cash losses amounting to Rs. 208 hundred during the current financial year and has incurred cash losses of Rs. 127 hundred during the immediately preceding financial year.
- (xviii) There has been no resignation of the statutory auditors of the Company during the year.
- (xix) On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- (xx) On the basis of information and explanations given to us and based on the examination of the records of the company, the provisions of Corporate Social Responsibility (“CSR”) of the Act is not applicable to the company. Accordingly, reporting under this clause of the Order is not applicable for the year.

For **MUKESH M. SHAH & CO.,**
Chartered Accountants
Firm Registration No.: 106625W

Place: Ahmedabad
Date: April 30, 2026
UDIN: 26129675BZFBWK2166

sd/-
Karnik K. Shah
Partner
Membership No.: 129675

“ANNEXURE B” TO THE AUDITORS’ REPORT

Report on the Internal Financial Control clause (i) of sub-section 3 of section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of **BIOCHEM PHARMACEUTICAL PRIAVTE LIMITED** (“the company”) as of March 31, 2026 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial control based on the internal control over financial reporting criteria established by the company considering the essential components of internal control stated in the Guidance Note on audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India [ICAI]. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors’ Responsibility

Our responsibility is to express an opinion on the company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Controls and, both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial control system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s Judgment, including the assessment of the material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal financial control over financial reporting includes those policies and procedures that:

1. pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
2. provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
3. provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Inherent limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **MUKESH M. SHAH & CO.,**
Chartered Accountants
Firm Registration No.: 106625W

Place: Ahmedabad
Date: April 30, 2026
UDIN: 26129675BZFBWK2166

sd/-
Karnik K. Shah
Partner
Membership No.: 129675

Balance Sheet as at March 31, 2026

Particulars	Note No.	INR-Hundred	
		As at March 31	
		2026	2025
ASSETS:			
Current Assets:			
Financial Assets:			
Cash and Cash Equivalents	3 [A]	388	196
Bank Balances other than Cash and Cash Equivalents	3 [B]	4,600	-
Total Current Assets		4,988	196
Total Assets		4,988	196
EQUITY AND LIABILITIES:			
Equity:			
Equity Share Capital	4	6,000	1,000
Other Equity	5	(1,142)	(931)
Total equity		4,858	69
Liabilities:			
Current Liabilities:			
Financial Liabilities:			
Trade Payables :			
Dues to Micro and Small Enterprises	6	118	118
Dues to Other than Micro and Small Enterprises	6	-	-
Other Financial Liabilities	7	9	9
Current Tax Liabilities [Net]	8	3	-
Total Current Liabilities		130	127
Total Equity and Liabilities		4,988	196
Material Accounting Policies	2		
Notes to the Financial Statements	3 to 21		

As per our report of even date

For Mukesh M. Shah & Co.

Chartered Accountants

Firm Registration Number: 106625W

For and on behalf of the Board

sd/-

Karnik K Shah

Partner

Membership Number:129675

Ahmedabad, Dated: April 30, 2026

sd/-

Mukund Thakkar

Director

DIN-02906462

Ahmedabad, Dated: April 30, 2026

sd/-

Vishal Gor

Director

DIN-08787850

Biochem Pharmaceutical Private Limited [CIN : U24304GJ2017PTC097977]

Statement of Profit and Loss for the year ended March 31, 2026

Particulars	Note No.	INR-Hundred	
		Year ended March 31	
		2026	2025
INCOME:			
Other Income	9	159	6
Total Income		159	6
EXPENSES:			
Finance Costs	10	3	3
Other Expenses	11	364	130
Total Expenses		367	133
Loss before Tax		(208)	(127)
Less: Tax Expense:			
Current Tax	12	3	-
		3	-
Loss for the year		(211)	(127)
Other Comprehensive Income for the year [Net of tax]		-	-
Total Comprehensive Loss for the year [Net of Tax]		(211)	(127)
Basic & Diluted Earnings per Equity Share [EPS] [in Rupees]	13	(0.52)	(1.27)
Material Accounting Policies	2		
Notes to the Financial Statements	3 to 21		

As per our report of even date

For and on behalf of the Board

For Mukesh M. Shah & Co.
Chartered Accountants
Firm Registration Number: 106625W

sd/-
Karnik K Shah
Partner
Membership Number:129675
Ahmedabad, Dated: April 30, 2026

sd/-
Mukund Thakkar
Director
DIN-02906462

sd/-
Vishal Gor
Director
DIN-08787850
Ahmedabad, Dated: April 30, 2026

Biochem Pharmaceutical Private Limited [CIN : U24304GJ2017PTC097977]		
Statement of Changes in Equity for the year ended March 31, 2026		
a Equity Share Capital:		
	No. of Shares	INR-Hundred
Equity Shares of INR 10/- each, Issued, Subscribed and Fully Paid-up [Refer Note-4]:		
As at March 31, 2024	10,000	1,000
As at March 31, 2025	10,000	1,000
Add: Issued during the year	50,000	5,000
As at March 31, 2026	60,000	6,000
b Other Equity:		
Retained Earning [Refer Note-5]		
As at March 31, 2024		(804)
Add: [Loss] for the year		(127)
As at March 31, 2025		(931)
Add: [Loss] for the year		(211)
As at March 31, 2026		(1,142)
<u>As per our report of even date</u> For Mukesh M. Shah & Co. Chartered Accountants Firm Registration Number: 106625W sd/- Karnik K Shah Partner Membership Number:129675 Ahmedabad, Dated: April 30, 2026		<u>For and on behalf of the Board</u> sd/- Mukund Thakkar Director DIN-02906462 Ahmedabad, Dated: April 30, 2026
		sd/- Vishal Gor Director DIN-08787850 Ahmedabad, Dated: April 30, 2026

Biochem Pharmaceutical Private Limited [CIN : U24304GJ2017PTC097977]

Cash Flow Statement for the year ended March 31, 2026

Particulars	INR-Hundred	
	Year ended March 31	
	2026	2025
A Cash flows from operating activities:		
[Loss] before Tax	(208)	(127)
Adjustments for:		
Interest Income	(159)	(6)
Total	(159)	(6)
Operating loss before working capital changes	(367)	(133)
Adjustments for:		
[Decrease] in other current liabilities	-	(3)
Total	-	(3)
Cash [used in] operating activities	(367)	(136)
Income taxes paid [Net of refunds]	-	-
Net cash [used in] operating activities	(367)	(136)
B Cash flows from investing activities:		
Investment [made in]/withdrawn from Fixed Deposit	(4,600)	230
Interest Received	159	6
Net cash [used in]/generated from investing activities	(4,441)	236
C Cash flows from financing activities:		
Proceeds from issue of Equity Shares	5,000	-
Net cash generated from financing activities	5,000	-
Net increase in cash and cash equivalents	192	100
Cash and cash equivalents at the beginning of the year	196	96
Cash and cash equivalents at the end of the year	388	196

Notes to the Cash Flow Statement

- The above cash flow statement has been prepared under the "Indirect method" as set out in Ind AS-7 "Statement of Cash Flows".
- All figures in brackets are outflows.
- Previous year's figures have been regrouped wherever necessary.
- Summary of Cash and cash equivalents and Bank Balances:

	INR-Hundred		
	Year ended March 31		
	2026	2025	2024
a Cash and cash equivalents	388	196	96
b Bank balance other than cash and cash equivalents	4,600	-	230
c Total	4,988	196	326

As per our report of even date

For Mukesh M. Shah & Co.

Chartered Accountants

Firm Registration Number: 106625W

For and on behalf of the Board

sd/-

Karnik K Shah

Partner

Membership Number:129675

Ahmedabad, Dated: April 30, 2026

sd/-

Mukund Thakkar

Director

DIN-02906462

Ahmedabad, Dated: April 30, 2026

sd/-

Vishal Gor

Director

DIN-08787850

Biochem Pharmaceutical Private Limited**Note: 1-Company overview:**

Biochem Pharmaceutical Private Limited ["the Company"] [CIN : U24304GJ2017PTC097977], a company limited by shares, incorporated on June 22, 2017 and domiciled in India, plans to operate as an integrated pharmaceutical company. The registered office of the Company is located at "Zydus Corporate Park", Scheme No. 63, Survey No. 536, Khoraj [Gandhinagar] Near Vaishnodevi Circle, S. G. Highway, Ahmedabad - 382481. These financial statements were authorised for issue in accordance with a resolution passed by the Board of Directors at their meeting held on April 30, 2026.

Note: 2-Material Accounting Policies:

A The following note provides list of the material accounting policies adopted in the preparation of these financial statements. These policies have been consistently applied to all the years presented unless otherwise stated.

1 Basis of preparation:

A The financial statements have been prepared in all material aspects in accordance with the Indian Accounting Standards [Ind AS] notified under section 133 of the Companies Act, 2013 read with [Indian Accounting Standards] Rules, 2015, as amended and other relevant provisions of the Companies Act, 2013.

B The financial statements have been prepared on historical cost basis, except for certain financial assets and liabilities measured at fair value [refer accounting policy regarding financial instruments] which have been measured at fair values at the end of the reporting periods.

2 Use of key Estimates and Judgements:

The preparation of the financial statements in conformity with Ind AS requires management to make estimates, judgments and assumptions. These estimates, judgments and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of income and expenses during the period. Application of accounting policies that require critical accounting estimates involving complex and subjective judgments are provided below. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the financial statements.

Critical accounting judgments and estimates:**a Taxes on Income:**

Significant judgments are involved in determining the provision for income taxes, including amount expected to be paid/recovered for uncertain tax positions. Refer Note-12.

b Contingent liabilities:

Significant judgment is involved in determining whether there is a possible obligation, that may, but probably will not require an outflow of resources.

3 Revenue Recognition:

The following are the accounting policies related to revenue recognition under Ind AS 115:

Interest Income:

Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Other Income:

Other income is recognised when no significant uncertainty as to its determination or realisation exists.

4 Taxes on Income:

Tax expenses comprise of current and deferred tax.

A Current Tax:

- a Current tax is measured at the amount expected to be paid on the basis of reliefs and deductions available in accordance with the provisions of the Income Tax Act, 1961. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date.
- b Current tax items are recognised in co-relation to the underlying transaction either in Profit or Loss, OCI or directly in equity.

B Deferred Tax:

- a Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.
- b Deferred tax liabilities are recognised for all taxable temporary differences.
- c Deferred tax assets are recognised for all deductible temporary differences including the carry forward of unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, the carry forward of unused tax credits and unused tax losses can be utilized.
- d The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.
- e Deferred tax assets and liabilities are measured at the tax rates [and tax laws] that have been enacted or substantively enacted at the reporting date and are expected to apply in the year when the asset is realised or the liability is settled.
- f Deferred tax items are recognised in co-relation to the underlying transaction either in profit or loss, OCI or directly in equity.
- g Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets

Note: 2-Material Accounting Policies-Continued:

against current tax liabilities.

5 Cash and Cash Equivalents:

Cash and Cash equivalents for the purpose of Cash Flow Statement comprise cash and cheques in hand, bank balances, demand deposits with banks where the original maturity is three months or less and other short term highly liquid investments.

6 Provisions, Contingent Liabilities and Contingent Assets:

- A** Provisions are recognised when the Company has a present obligation as a result of past events and it is probable that the outflow of resources will be required to settle the obligation and in respect of which reliable estimates can be made. A disclosure of contingent liability is made when there is a possible obligation, that may, but probably will not require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision/ disclosure is made. Provisions and contingencies are reviewed at each balance sheet date and adjusted to reflect the correct management estimates. Contingent assets are not recognised but are disclosed separately in financial statements.
- B** If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability.

7 Financial Instruments:

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

A Financial Assets:

a Initial recognition and measurement:

All financial assets are recognised initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction cost that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place [regular way trades] are recognised on the settlement date, i.e., the date that the Company settles to purchase or sell the asset. However, trade receivables that do not contain a significant financing component are measured at transaction price.

b Derecognition:

A financial asset [or, where applicable, a part of a financial asset] is primarily derecognised [i.e. removed from the Company's balance sheet] when:

- i The rights to receive cash flows from the asset have expired, or
- ii The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either [a] the Company has transferred substantially all the risks and rewards of the asset, or [b] the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained. When the Company has transferred the risks and rewards of ownership of the financial asset, the same is derecognised.

c Impairment of financial assets:

The Company follows 'simplified approach' for recognition of impairment loss allowance for any contractual right to receive cash or another financial asset. The application of simplified approach does not require the Company to track changes in credit risk. Rather, it requires the Company to recognise the impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

For recognition of impairment loss on other financial assets and risk exposure, the Company determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If, in a subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the entity reverts to recognising impairment loss allowance based on 12-month ECL. Lifetime ECL are the expected credit losses resulting from all possible default events over the expected life of a financial instrument.

ECL impairment loss allowance [or reversal] is recognized as expense/ income in the Statement of profit and loss. The balance sheet presentation for various financial instruments is described below:

Financial assets measured as at amortised cost: ECL is presented as an allowance, i.e., as an integral part of the measurement of those assets in the balance sheet, which reduces the net carrying amount. Until the asset meets write-off criteria, the Company does not reduce impairment allowance from the gross carrying amount.

For assessing increase in credit risk and impairment loss, the Company combines financial instruments on the basis of shared credit risk characteristics.

B Financial Liabilities:

a Initial recognition and measurement:

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate. All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

b Subsequent measurement:

Subsequently all financial liabilities are measured at amortised cost, using EIR method. Gains and losses are recognised in Statement of profit and loss when the liabilities are derecognised as well as through the EIR amortisation process. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included

Note: 2-Material Accounting Policies-Continued:

as finance costs in the Statement of profit and loss.

c Derecognition:

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the Statement of profit and loss.

C Reclassification of financial assets:

The Company determines classification of financial assets and liabilities on initial recognition. After initial recognition, no reclassification is made for financial assets which are equity instruments and financial liabilities. For financial assets which are debt instruments, a reclassification is made only if there is a change in the business model for managing those assets. Changes to the business model are expected to be infrequent. The Company's senior management determines change in the business model as a result of external or internal changes which are significant to the Company's operations. Such changes are evident to external parties. A change in the business model occurs when the Company either begins or ceases to perform an activity that is significant to its operations. If the Company reclassifies financial assets, it applies the reclassification prospectively from the reclassification date which is the first day of the immediately next reporting period following the change in business model as per Ind AS 109.

D Offsetting of financial instruments:

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

8 Fair Value Measurement:

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- a In the principal market for the asset or liability, or
- b In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use. The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the standalone financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- a Level 1 — Quoted [unadjusted] market prices in active markets for identical assets or liabilities
- b Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
- c Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the standalone financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation [based on the lowest level input that is significant to the fair value measurement as a whole] at the end of each reporting period.

9 Earnings per Share:

Basic earnings per share is calculated by dividing the net profit or loss [excluding other comprehensive income] for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. The weighted average number of equity shares outstanding during the year is adjusted for events such as bonus issue, bonus element in a right issue, shares split and reserve share splits [consolidation of shares] that have changed the number of equity shares outstanding, without a corresponding change in resources. For the purpose of calculating diluted earnings per share, the net profit or loss [excluding other comprehensive income] for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

B Recent Accounting Pronouncements:

The Ministry of Corporate Affairs [MCA] notifies new standards or amendments to existing standards under the Companies [Indian Accounting Standards] Rules from time to time. MCA has notified amendments to Ind AS 1 – Presentation of Financial Statements [classification of liabilities as Current or Non-current, including liabilities with covenants], Ind AS 12 – Income Taxes [International Tax Reform – Pillar Two Model Rules], Ind AS 21 – The Effects of Changes in Foreign Exchange Rates [Lack of Exchangeability] and Ind AS 7 – Statement of Cash Flows and Ind AS 107 – Financial Instruments: Disclosures [Supplier Finance Arrangements], effective from April 1, 2025. The Company has reviewed these amendments and based on its evaluation, has determined that they do not have any material impact on the Company's financial statements.

New standards or amendments not yet adopted:

Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants – Amendments to Ind AS 1. The amendments clarify that lender waivers obtained after the reporting date cannot be considered for the purpose of classifying liabilities as current or non current and require retrospective application in accordance with Ind AS 8. These amendments are effective for reporting periods beginning on or after April 1, 2026. The Company has no impact of these amendments in its classification criteria of current and non-current liabilities.

Biochem Pharmaceutical Private Limited																									
						INR-Hundred																			
						As at March 31																			
						2026	2025																		
Note: 3-Cash and Cash Equivalents:																									
A Cash and Cash Equivalents: Balances with Banks Total There are no amounts of cash and cash equivalent balances held by the entity that are not available for use.						388	196																		
						388	196																		
B Bank Balances other than Cash and Cash Equivalents: Fixed deposits Total The Company keeps fixed deposits with the Nationalised/ Scheduled banks, which can be withdrawn by the company as per its own discretion/ requirement of funds.						4,600	-																		
						4,600	-																		
Note: 4-Equity Share Capital:																									
Authorised: 60,000 [as at March 31, 2025: 10,000] Equity Shares of INR 10/- each [*] Issued, Subscribed and Paid-up: 60,000 [as at March 31, 2025: 10,000] Equity Shares of INR 10/- each, fully paid-up [*] Total A The reconciliation in number of Equity shares is as under: Number of shares at the beginning of the year Add: Issued during the year [*] Number of shares at the end of the year [*] The Company has increased its authorised share capital by 50,000 Equity Shares of INR 10/- each by passing special resolution in its annual general meeting held on August 1, 2025. After approval of the board in its meeting held on August 22, 2025 the same 50,000 Equity Shares were issued and allotted to its Holding Company Zydus Animal Health and Investments Limited on August 22, 2025. B The Company has only one class of equity shares having a par value of INR 10/- per share. Each holder of equity share is entitled to one vote per share. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the Annual General Meeting, except in the case of interim dividend. In the event of liquidation of the Company, the equity shareholders shall be entitled to proportionate share of their holding in the assets remaining after distribution of all preferential amounts. C Details of Shareholder holding more than 5% of aggregate Equity Shares of INR 10/- each: Zydus Animal Health and Investments Limited along with its nominees Number of Shares % to total share holding D Details of Equity Shares held by promoters / promoter group at the end of the years March 31, 2026 and year end March 31, 2025:						6,000	1,000																		
						6,000	1,000																		
						6,000	1,000																		
						6,000	1,000																		
						10,000	10,000																		
						50,000	-																		
						60,000	10,000																		
						60,000 100%	10,000 100%																		
<table><tr><th rowspan="2">#</th><th rowspan="2">Promoter's/ Promoter Group's Name</th><th colspan="2">As at March 31, 2026</th><th colspan="2">As at March 31, 2025</th><th rowspan="2">% change during the year</th></tr><tr><th>No. of Shares</th><th>% of total shares</th><th>No. of Shares</th><th>% of total shares</th></tr><tr><td>1</td><td>Zydus Animal Health and Investments Limited along with its nominees</td><td>60,000</td><td>100.00%</td><td>10,000</td><td>100.00%</td><td>0.00%</td></tr></table>						#	Promoter's/ Promoter Group's Name	As at March 31, 2026		As at March 31, 2025		% change during the year	No. of Shares	% of total shares	No. of Shares	% of total shares	1	Zydus Animal Health and Investments Limited along with its nominees	60,000	100.00%	10,000	100.00%	0.00%		
#	Promoter's/ Promoter Group's Name	As at March 31, 2026		As at March 31, 2025				% change during the year																	
		No. of Shares	% of total shares	No. of Shares	% of total shares																				
1	Zydus Animal Health and Investments Limited along with its nominees	60,000	100.00%	10,000	100.00%	0.00%																			
Note: 5-Other Equity:																									
Retained Earnings: Balance as per last Balance Sheet Add: [Loss] for the year Balance as at the end of the year						(931)	(804)																		
						(211)	(127)																		
						(1,142)	(931)																		

Biochem Pharmaceutical Private Limited						
					INR-Hundred	
					As at March 31	
					2026	2025
Note: 6-Trade Payables:						
Dues to Micro and Small Enterprises [*]					118	118
Dues to other than Micro and Small Enterprises					-	-
Total					118	118
[*] Disclosure in respect of Micro and Small Enterprises:					118	118
A Principal amount remaining unpaid to any supplier as at year end						
B Interest due thereon						
C Amount of interest paid by the Company in terms of section 16 of the Micro, Small and Medium Enterprises Act, along with the amount of the payment made to the supplier beyond the appointed day during the year						
D Amount of interest due and payable for the year of delay in making payment [which have been paid but beyond the appointed day during the year] but without adding the interest specified under the MSMED Act						
E Amount of interest accrued and remaining unpaid at the end of the accounting year						
F Amount of further interest remaining due and payable in succeeding years						
The above information has been compiled in respect of parties to the extent to which they could be identified as Micro and Small Enterprises on the basis of information available with the Company						
Ageing of Trade Payables :						
Particulars	Not due	Outstanding from due date of payment				Total
		Less than 1 year	1 to 2 years	2 to 3 years	More than 3 years	
		As at March 31, 2026				
Undisputed Micro and Small Enterprises [MSME]	118	-	-	-	-	118
Undisputed Others	-	-	-	-	-	-
Disputed MSME	-	-	-	-	-	-
Disputed Others	-	-	-	-	-	-
Total	118	-	-	-	-	118
		As at March 31, 2025				
Undisputed Micro and Small Enterprises [MSME]	118	-	-	-	-	118
Undisputed Others	-	-	-	-	-	-
Disputed MSME	-	-	-	-	-	-
Disputed Others	-	-	-	-	-	-
Total	118	-	-	-	-	118
					INR-Hundred	
					As at March 31	
					2026	2025
Note: 7-Other Current Financial Liabilities:						
Accrued expenses					9	9
Total					9	9
Note: 8-Current Tax Liabilities [Net]:						
Provision for Taxation [Net of advance payment of tax of INR Nil {as at March 31, 2025: INR Nil}]					3	-
Total					3	-

Biochem Pharmaceutical Private Limited			
Notes to the Financial Statements			
		INR-Hundred	
		Year ended March 31	
		2026	2025
Note: 9-Other Income:			
Finance Income:			
Interest Income on Financial Assets measured at Amortised Cost		159	6
Total		159	6
Note: 10-Finance Cost:			
Bank commission & charges		3	3
Total		3	3
Note: 11-Other Expenses:			
Legal and Professional Fees [*]		364	130
Total		364	130
[*] Legal and Professional Fees include:			
Payment to the Statutory Auditors [excluding GST]:			
i As Auditor		100	100
ii For Other Services		-	-
iii Total		100	100
Note: 12-Tax Expenses:			
The major components of income tax expense are:			
A Statement of profit and loss:			
Current income tax:			
Current income tax charge		3	-
Tax expense reported in the statement of profit and loss		3	-
B Reconciliation of tax expense and accounting profit multiplied by India's domestic tax rate:			
Loss before tax		(208)	(127)
Enacted Tax Rate (%) of the Country		26.00%	26.00%
Expected Tax Expenses		(54)	(33)
Adjustments for:			
Effect of non-deductible expenses		57	33
Others		-	-
Total		57	33
Tax Expenses as per Statement of Profit and Loss		3	-
Note: 13-Calculation of Earnings per Equity Share [EPS]:			
The numerators and denominators used to calculate the basic and diluted EPS are as follows:			
A (Loss) attributable to Equity Share Holders	INR-Hundred	(211)	(127)
B Basic number of Equity shares outstanding during the year	Numbers	60,000	10,000
C Weighted average number of Equity Shares outstanding during the year	Numbers	40,411	10,000
D Nominal value of equity share	INR	10	10
E Basic & Diluted EPS	INR	(0.52)	(1.27)
Note: 14-Segment Information:			
The Company has not carried out any commercial activity during the year, hence, segment reporting is not required.			

Biochem Pharmaceutical Private Limited
Notes to the Financial Statements

Note: 15-Related Party Transactions:

A Name of the Related Parties and Nature of the Related Party Relationship:

a Holding Company:	Zydus Animal Health and Investments Limited [ZAHIL]
b Ultimate Holding Company:	Zydus Lifesciences Limited [ZLL]
c Fellow Subsidiary Companies/ concerns:	
Zydus Healthcare Limited	Zydus Pharmaceuticals (USA) Inc. [ZPUI] [USA]
German Remedies Pharmaceuticals Private Limited	Nesher Pharmaceuticals (USA) LLC [USA] [Merged with ZPUI w.e.f. October 25, 2024]
Zydus Wellness Limited	ZyVet Animal Health Inc. [USA]
Zydus Wellness Products Limited	Zydus Healthcare (USA) LLC [USA]
Liva Nutritions Limited	Sentynl Therapeutics Inc. [USA]
Liva Investment Limited [upto August 20, 2025]	Viona Pharmaceuticals Inc. [USA]
Dialforhealth Unity Limited	Zydus Therapeutics Inc. [USA]
Dialforhealth Greencross Limited	Zynext Ventures USA LLC [USA]
Violio Healthcare Limited	Zydus Healthcare S.A. (Pty) Ltd [South Africa]
Zydus Pharmaceuticals Limited	Alidac Pharmaceuticals SA Pty. Ltd. [South Africa]
Zydus Strategic Investments Limited	Script Management Services (Pty) Ltd [South Africa]
Zydus VTEC Limited	Zydus Wellness [BD] Pvt Ltd [Bangladesh]
LM Manufacturing India Private Limited	Zydus Pharmaceuticals Mexico SA De C.V. [Mexico]
M/s. Recon Pharmaceuticals and Investments, a Partnership Firm	Zydus Worldwide DMCC [UAE]
Zydus Medtech Private Limited [w.e.f. May 31, 2024]	Zydus Pharmaceuticals Mexico Services Company SA De C.V.[Mexico]
Naturell (India) Private Limited [w.e.f. December 2, 2024, under liquidation]	Zydus Wellness International DMCC [UAE]
Zydus International Private Limited [Ireland]	Zydus Lifesciences Global FZE [UAE]
Zydus Netherlands B.V. [the Netherlands]	Zydus Pharmaceuticals (Canada) Inc. [Canada]
Zydus Lanka (Private) Limited [Sri Lanka]	Zydus Pharmaceuticals UK Limited [UK]
Zydus Nikkho Farmaceutica Ltda. [Brazil]	LM Manufacturing Limited [UK]
Alidac Healthcare (Myanmar) Limited [Myanmar]	Medsolutions (Europe) Limited [UK]
Zydus Healthcare Philippines Inc. [Philippines]	LiqMeds Worldwide Limited [UK]
Zynext Ventures PTE. LTD. [Singapore]	LiqMeds Limited [UK]
Zydus France, SAS [France]	LiqMeds Lifecare Limited [UK] [LiqMed]
Laboratorios Combix S.L. [Spain]	Naturell Inc. [USA] [w.e.f. December 2, 2024]
Etna Biotech S.R.L. [Italy] [Under Liquidation]	Amplitude Nord SAS [France] [w.e.f. July 29, 2025]
Zylidac Bio LLC [USA] [w.e.f. July 11, 2025]	Ortho Santé (Amplitude Ouest) [France] [w.e.f. July 29, 2025]
Zydus MedTech (France) SAS [France] [w.e.f. April 10, 2025]	Amplitude Benelux [Belgium] [w.e.f. July 29, 2025]
Amplitude Surgical SAS [France] [w.e.f. July 29, 2025]	Amplitude Suisse SA [Switzerland] [w.e.f. July 29, 2025]
Amplitude Orthopedics Corporation [USA] [w.e.f. July 29, 2025]	Amplitude GmbH [Germany] [w.e.f. July 29, 2025]
Amplitude Australia Pty Ltd [Australia] [w.e.f. July 29, 2025]	Amplitude New Zealand Limited [New Zealand] [w.e.f. July 29, 2025]
Amplitude South Africa Pty Ltd [South Africa] [w.e.f. July 29, 2025]	Ampliman 1 [France] [w.e.f. July 29, 2025 till January 16,2026]
Amplitude Latin America SA [Brazil] [w.e.f. July 29, 2025]	Ampliman 2 [France] [w.e.f. July 29, 2025 till January 9,2026]
Amplitude SAS [France] [w.e.f. July 29, 2025]	Mediconseil [w.e.f. December 19, 2025]
SCI Les Tilleuls [France] [w.e.f. July 29, 2025]	Alidac UK Limited [w.e.f. August 5, 2025]
SCI SOFAB FALLA [France] [w.e.f. July 29, 2025]	Comfort Click Limited [UK] [w.e.f August 29,2025]
Amplitude Ile de France [France] [w.e.f. July 29, 2025]	Comfort Click Limited [Ireland] [w.e.f August 29,2025]
Duotech Amplitude SAS [France] [w.e.f. July 29, 2025]	Comfort Click LLC [USA] [w.e.f August 29,2025]
Amplitude Sud SAS [France] [w.e.f. July 29, 2025]	
Auroralux [Luxemburg] [w.e.f. July 29, 2025 till December 31,2025]	
Comfort Click Softech Pvt. Ltd. [w.e.f August 29,2025]	
d Joint Venture [JV] Companies:	
Zydus Hospira Oncology Private Limited [JV of ZLL]	Zydus Takeda Healthcare Private Limited [JV of ZLL]
Bayer Zydus Pharma Private Limited [JV of ZLL] [up to May 02, 2024]	Oncosol Limited [JV of LiqMed]
Sterling Biotech Limited [w.e.f. August 29, 2024] [JV of ZAHIL]	
e Directors	
Mr. Mukund Thakkar	Director
Mr. Harish Sadana	Director
Mr. Vishal Gor	Director

Biochem Pharmaceutical Private Limited
Notes to the Financial Statements

Note: 15-Related Party Transactions-Continued:

B Transactions with Related Parties:

Details relating to parties referred to in Note-15-A [a, b, c & d]

Value of the Transactions [INR-Hundred]

Nature of Transactions	Holding Company		Fellow Subsidiary Companies		Enterprises significantly influenced by Directors and/ or their relatives	
	Year ended March 31		Year ended March 31		Year ended March 31	
	2026	2025	2026	2025	2026	2025
Issue of Share Capital:						
Zydus Animal Health and Investments Limited	5,000	-	-	-	-	-

Note: 16-Financial Instruments:

Financial Assets:

The carrying amounts of cash and cash equivalents are considered to be the approximately equal to the fair values.

Financial Liabilities:

Fair values of other financial liabilities are considered to be approximately equal to the carrying values.

Note: 17-Financial Risk Management:

A Financial instruments by category:

	INR-Hundred			
	As at March 31, 2026			
	FVTPL	FVOCI	Amortised Cost	Total
Financial assets:				
Cash and Cash Equivalents	-	-	388	388
Bank Balances other than Cash and Cash Equivalents	-	-	4,600	4,600
Total	-	-	4,988	4,988
Financial liabilities:				
Trade payables	-	-	118	118
Other Current Financial Liabilities	-	-	9	9
Total	-	-	127	127
	As at March 31, 2025			
Financial assets:				
Cash and Cash Equivalents	-	-	196	196
Total	-	-	196	196
Financial liabilities:				
Trade payables	-	-	118	118
Other Current Financial Liabilities	-	-	9	9
Total	-	-	127	127

B Risk Management:

The Company's activities expose it to liquidity risk. This note explains the sources of risk which the entity is exposed to and how the entity manages the risk and the related impact in the financial statements. The Company's risk management is done in close co-ordination with the board of directors and focuses on actively securing the Company's cash flows by minimizing the exposure to volatile financial markets. The Company does not actively engage in the trading of financial assets for speculative purposes nor does it write options. The most significant financial risks to which the Company is exposed are described below:

a Credit risk:

Credit risk arises from the possibility that counter party may not be able to settle its obligations as agreed. The Company is exposed to credit risk from bank deposits and other financial assets. The Company periodically assesses the financial reliability of the counter party taking into account the financial condition, current economic trends, analysis of historical bad debts and ageing of accounts receivable.

b Liquidity risk:

- Prudent liquidity risk management implies maintaining sufficient cash and marketable securities to meet obligations when due.
- The Company takes into account the liquidity of the market in which it operates.

Maturities of financial liabilities:

The tables below analyse the Company's financial liabilities into relevant maturity groupings based on their contractual maturities for all

Biochem Pharmaceutical Private Limited
Notes to the Financial Statements

Note: 17-Financial Risk Management-Continued:

non-derivative financial liabilities. The amounts disclosed in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances as the impact of discounting is not significant.

	INR-Hundred				
	As at March 31, 2026				
	< 1 year	1-2 year	2-3 year	> 3 years	Total
Non-derivative Financial Liabilities:					
Trade payables	118	-	-	-	118
Other Current Financial Liabilities	9	-	-	-	9
Total	127	-	-	-	127
	As at March 31, 2025				
	As at March 31, 2025				
	< 1 year	1-2 year	2-3 year	> 3 years	Total
Non-derivative Financial Liabilities:					
Trade payables	118	-	-	-	118
Other Current Financial Liabilities	9	-	-	-	9
Total	127	-	-	-	127

Note: 18-Analytical Ratios:

#	Ratio	Numerator	Denominator	FY 25-26	FY 24-25	% Change
1	Current Ratio [\$]	Current Assets	Current Liabilities	38.37	1.54	2386.2%
2	Debt-Equity Ratio	Total Debt	Shareholder's Equity	NA	NA	NA
3	Debt Service Coverage Ratio	Earnings available for debt service	Finance cost + Repayment of debt	NA	NA	NA
4	Return on Equity Ratio [*]	Net profit after taxes + exceptional items	Average Shareholder's Equity	-8.6 %	-95.8%	-91.1%
5	Inventory turnover ratio	Net Sales	Average Inventory	NA	NA	NA
6	Trade Receivables turnover ratio	Net Sales	Average Trade Receivables	NA	NA	NA
7	Trade payables turnover ratio	Net Purchases and Other Expenses	Average Trade Payables	NA	NA	NA
8	Net capital turnover ratio	Net Sales	Average Working Capital	NA	NA	NA
9	Net profit ratio	Net profit after taxes + exceptional items	Net Sales	NA	NA	NA
10	Return on Capital employed [*]	Earnings before interest and taxes	Average Capital Employed	-8.4 %	-95.8%	-91.2%
11	Return on investment in Fixed Deposits	Income from investments during the year	Time weighted average of investments	6.6 %	6.8%	-2.22%

[\$] Due to increase in bank balances other than cash and cash equivalents.

[*] Due to increase in capital employed during the year on account of issue of share capital.

Note: 19:

- [a] The Company has not advanced or loaned or invested funds (either from borrowed funds or share premium or any other sources or kind of funds) to any other persons or entities, including foreign entities [Intermediaries], with the understanding, whether recorded in writing or otherwise, that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company [Ultimate Beneficiaries] or provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- [b] The Company has not received any funds from any persons or entities, including foreign entities [Funding Party] with the understanding [whether recorded in writing or otherwise], that the Company shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party [Ultimate Beneficiaries] or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- [c] The Company has used accounting software for maintaining its books of accounts for the year ended on March 31, 2026 which has a feature of recording audit trail [edit log] facility and the same has been operational throughout the year for all relevant transactions recorded in the software. Audit trail has been preserved by the Company as per the statutory requirements for record retention.
- [d] The Company has not traded or invested in Crypto currency or Virtual currency during the financial year.
- [e] No proceedings have been initiated or pending against the Company for holding any benami property under the Benami Transactions [Prohibition] Act, 1988 (45 of 1988) and the rules made thereunder.
- [f] The Company has not been declared as wilful defaulter by any bank or financial Institution or other lender.
- [g] The Company does not have any charges or satisfaction yet to be registered with Registrar of Companies beyond the statutory period.
- [h] The Company has complied with the number of layers prescribed under clause [87] of section 2 of the Act read with Companies [Restriction on number of Layers] Rules, 2017.
- [i] No Scheme of Arrangements has been approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013.
- [j] The Company does not have any transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 [such as, search or survey or any other relevant provisions of the Income Tax Act, 1961].

Biochem Pharmaceutical Private Limited
Notes to the Financial Statements

Note: 20-Disclosure of transactions with Struck off Companies:

The Company did not have any transaction with companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of Companies Act, 1956 during the current and previous financial year.

Note: 21:

Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure.

Signatures to Material Accounting Policies and Notes 1 to 21 to the Financial Statements

As per our report of even date

For and on behalf of the Board

For Mukesh M. Shah & Co.

Chartered Accountants

Firm Registration Number: 106625W

sd/-

Karnik K Shah

Partner

Membership Number:129675

Ahmedabad, Dated: April 30, 2026

sd/-

Mukund Thakkar

Director

DIN-02906462

Ahmedabad, Dated: April 30, 2026

sd/-

Vishal Gor

Director

DIN-08787850